- Home
- CASI vs MURA Comparison
CASI vs MURA Comparison
Compare CASI & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- MURA
- Stock Information
- Founded
- CASI 1991
- MURA 2013
- Country
- CASI China
- MURA Ireland
- Employees
- CASI N/A
- MURA N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- MURA
- Sector
- CASI Health Care
- MURA
- Exchange
- CASI Nasdaq
- MURA Nasdaq
- Market Cap
- CASI 35.8M
- MURA 35.7M
- IPO Year
- CASI 1996
- MURA N/A
- Fundamental
- Price
- CASI $2.28
- MURA $2.08
- Analyst Decision
- CASI Strong Buy
- MURA Strong Buy
- Analyst Count
- CASI 1
- MURA 3
- Target Price
- CASI $4.00
- MURA $12.00
- AVG Volume (30 Days)
- CASI 384.8K
- MURA 467.6K
- Earning Date
- CASI 11-13-2025
- MURA 11-12-2025
- Dividend Yield
- CASI N/A
- MURA N/A
- EPS Growth
- CASI N/A
- MURA N/A
- EPS
- CASI N/A
- MURA N/A
- Revenue
- CASI $31,564,000.00
- MURA N/A
- Revenue This Year
- CASI N/A
- MURA N/A
- Revenue Next Year
- CASI N/A
- MURA N/A
- P/E Ratio
- CASI N/A
- MURA N/A
- Revenue Growth
- CASI 36.64
- MURA N/A
- 52 Week Low
- CASI $1.09
- MURA $0.95
- 52 Week High
- CASI $7.55
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- CASI 55.66
- MURA 52.67
- Support Level
- CASI $2.18
- MURA $2.05
- Resistance Level
- CASI $2.49
- MURA $2.09
- Average True Range (ATR)
- CASI 0.19
- MURA 0.01
- MACD
- CASI -0.03
- MURA 0.02
- Stochastic Oscillator
- CASI 33.33
- MURA 75.00
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.